Paper Review Records
All Paper Review Records
22 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
113
days
Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine
Authors
Ting Shi; Ruicong Xue; Jing Jia; Menghan Liu; Yalan Zhou; Chuanying Geng; Yuan Jian; Ying Tian; Yanru Zhang; Wenjing Li; Lefu Huang; Huixing Zhou; Aijun Liu; Wen Gao; Wenming Chen; Yun Leng; Yin Wu; Hong-Hu ZhuShow moreShow less
Affiliations
1. Department of Hematology, Beijing Chao-Yang Hospital, Beijing, China; 2. Institute for Cancer, Chinese Institutes for Medical Research, Beijing, China; 3. Beijing Key Laboratory of Tumor Resistance Mechanism and Clinical Translation, Beijing, ChinaShow moreShow less
78
days
Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study
Authors
Lei Ju; Sifeng Gao; JiLei Zhang; Yuyu Liu; Qiang Song; Lin Dong; Yan Guo; Xuemei Qin; Jie Zou; Chenglu Yuan; Yan Shi; Dexiao Kong; Kaifeng Wang; Qiang Li; Donglin Yang; Qingliang Teng; Erlie Jiang; Jun Peng; Guanchen BaiShow moreShow less
Affiliations
1. Department of Hematology, The Affiliated Tai’an City Central Hospital of Qingdao University, Taian, China; 2. Department of Hematology, Qilu Hospital of Shandong University, Jinan, China; 3. Department of Hematology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China; 4. Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China; 5. Department of Hematology, The Qilu Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; 6. Department of Hematology, People’s Hospital of Zhangqiu District, Jinan, China; 7. Department of Hematology, Liaocheng People’s Hospital, Liaocheng City, China; 8. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; 9. State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Department of Hematology, Qilu Hospital of Shandong University, Jinan, ChinaShow moreShow less
65
days
Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Authors
Chenying Li; Hongyan Tong; Huafeng Wang; Yanling Ren; Jiejing Qian; Xinping Zhou; Gaixiang Xu; Liangshun You; Liping Mao; Haitao Meng; Wenjuan Yu; Xingnong Ye; Min Yang; Jian Huang; De Zhou; Wanzhuo Xie; Jie Jin; Yinjun LouShow moreShow less
Affiliations
1. Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China; 2. Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China; 3. Zhejiang Provincial Clinical Research Center For Hematological disorders, Hangzhou, PR China; 4. Zhejiang University Cancer Center, Hangzhou, PR ChinaShow moreShow less
119
days
Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes
Authors
Masataka Sakashita; Junya Kanda; Keiichiro Hattori; Nobuhiro Hiramoto; Nobuhiro Kanemura; Senji Kasahara; Mitsumasa Watanabe; Satoshi Yoshihara; Michiko Ichii; Nobuo Sezaki; Masaaki Tsuji; Takeshi Maeda; Ko Sasaki; Toshiyuki Kitano; Yasuko Miyahara; Tadakazu Kondo; Mamiko Sakata-Yanagimoto; Akifumi Takaori-Kondo; Seishi Ogawa; Yasuhito NannyaShow moreShow less
Affiliations
1. Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 2. Department of Hematology, Kanazawa University Hospital, Kanazawa University, Ishikawa, Japan; 3. Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 4. Department of Hematology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan; 5. Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan; 6. Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan; 7. Department of Hematology, Gifu Municipal Hospital, Gifu, Japan; 8. Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan; 9. Department of Hematology, Hyogo Medical University Hospital, Hyogo, Japan; 10. Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Osaka, Japan; 11. Department of Hematology, Chugoku Central Hospital, Hiroshima, Japan; 12. Department of Hematology and Immunology, Japanese Red Cross Otsu Hospital, Otsu, Japan; 13. Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan; 14. Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan; 15. Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan; 16. Department of Hematology, Kyoto City Hospital, Kyoto, Japan; 17. Department of Hematology, University of Tsukuba Hospital, Division of Advanced Hemato-Oncology, Tsukuba, Japan; 18. Transborder Medical Research Center, University of Tsukuba, Tsukuba, Japan; 19. Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; 20. Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, JapanShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days